Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Celldex Therapeutics Inc's CDX-301 in combination with Mozobil increases hematopoietic stem cell mobilization and results in improved transplantation of mobilized cells in preclinical studies


Tuesday, 10 Dec 2013 08:30am EST 

Celldex Therapeutics Inc:Says positive results from a preclinical combination study of CDX-301 (FMS-like tyrosine kinase-3 ligand or Flt3L) and Mozobil (Plerixafor injection, formerly AMD3100) demonstrating that the combination of these agents significantly increases hematopoietic stem cell mobilization in mice.Says the data support future clinical development of CDX-301 and demonstrate a potent cell mobilization regimen combining CDX-301 and Mozobil, which may have significant potential for use in autologous and allogeneic hematopoietic stem cell transplantation.Says results were presented in an oral session entitled FLT3L and AMD3100 Combination Increases Hematopoietic Stem Cell Mobilization and Leads to Improved Transplantation Outcome on Dec. 10 at the American Society of Hematology 55th Annual Meeting and Exposition (ASH).Says the studies were conducted in collaboration with Jianhua Yu, PhD, and Steven Devine, MD, and were presented by Shun He, PhD, all of The Ohio State University.Says this study found that the combination of CDX-301 and Mozobil mobilized the highest rate and amount of hematopoietic stem cells into peripheral blood compared to the mice treated with granulocyte colony-stimulating factor alone, or the combination of G-CSF with Mozobil. 

Company Quote

20.28
-0.26 -1.27%
28 Nov 2014